Camacho MA, Alfonso AD, Arreaza GM, Molina GS, Buitrago LM

Idioma: Español
Referencias bibliográficas: 27
Paginas: 69-84
Archivo PDF: 451.97 Kb.

RESUMEN

Objetivo: Determinar si la exposición al ondansetrón en el primer trimestre del embarazo se asocia, en general, con mayor riesgo de malformaciones orofaciales, cardiopatías congénitas, defectos del septo interventricular, de labio o paladar hendidos.
Metodología: Revisión sistemática y metanálisis de estudios aleatorizados, cohortes y casos y controles publicados en las bases de datos de PubMed, EMBASE y LILACS.
Resultados: Se incluyeron 15 estudios: 11 de cohorte y 4 de casos y controles, con 245,679 mujeres expuestas al ondansetrón en el primer trimestre del embarazo. No se encontró una asociación estadísticamente significativa con malformaciones congénitas en general (RM 1.1; IC95%: 0.99-1.22; I2: 72%), con cardiopatías congénitas (RM 1.05; IC95%: 0.95-1.19; I2: 78%) y con comunicación interventricular (RM 1.2; IC95%: 0.97- 1.45; I2: 85%). Se encontró un pequeño aumento en el riesgo de defectos orofaciales en general (RM 1.17; IC95%: 1.04-1.32; I2:0%), no se encontró un riesgo mayor de defecto de labio (RM 1.01; IC95%: 0.84-1.21; I2%: 0%) ni de paladar hendido (RM 1.16; IC95%: 0.9-1.5; I2: 31%).
Conclusión: Los resultados muestran que el tratamiento con ondansetrón en el primer trimestre del embarazo no se asocia con un aumento de malformaciones congénitas en general, ni con un incremento de cardiopatías, labio o paladar hendido, pero sí con incremento leve del riesgo de malformaciones orofaciales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Siminerio LL, Bodnar LM, Venkataramanan R, Caritis SN.Ondansetron Use in Pregnancy. Obstet Gynecol 2016; 127(5): 873-77. doi: 10.1097/AOG.0000000000001375

2. Slattery J, Quinten C, Candore G, Pinheiro L, Flynn R, KurzX, et al. Ondansetron use in nausea and vomiting duringpregnancy: A descriptive analysis of prescription patternsand patient characteristics in UK general practice. Br J ClinPharmacol 2022; 88 (10): 4526-39.

3. Danielsson B, Wikner BN, Källén B. Use of ondansetronduring pregnancy and congenital malformations in theinfant. Reprod Toxicol 2014; 50: 134-7. doi: 10.1016/j.reprotox.2014.10.017

4. Pasternak B, Svanström H, Hviid A. Sakran R, ShechtmanS, Arnon J, Diav-Citrin O. Pregnancy outcome following inuteroexposure to ondansetron: A prospective comparativeobservational study. Reprod Toxicol 2021; 99: 9-14. doi:10.1016/j.reprotox.2020.11.005

5. Huybrecht KF, Hernández-DíazS, StraubL, et al. Associationof maternal first-trimester ondansetron use with cardiacmalformations and oral clefts in offspring. JAMA 2018; 320(23): 2429-37. doi:10.1001/jama.2018.18307

6. Zambelli-WeinerA,ViaC,YuenM,WeinerDJ, Kirby RS. Firsttrimester ondansetron exposure and risk of structural birthdefects. Reprod Toxicol 2019; 83: 14-20. doi:10.1016/j.reprotox.2018.10.010

7. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-

8. 8-11-july-2019-prac-meeting_en.pdf8. Wells G, Shea B, D. O’Connell, et al. The Newcastle-OttawaScale (NOS) for Assessing the Quality of NonrandomisedStudies in Meta-analyses (2019).

9. Schrager NL, Parker SE, Werler MM, for the NationalBirth Defects Prevention Study. The association of nauseaand vomiting of pregnancy, its treatments, and select birthdefects: Findings from the National Birth Defect PreventionStudy. Birth Defects Res 2023; 115 (3): 275-28. doi:

10. 10.1002/bdr2.209610. Van Bennekom CM, Park SE, Anderka M, Louik C, MitchellAA. Ondansetron for the treatment of nausea and vomitingof pregnancy and the risk of birth defects. Pharma- coepidemiolDrug Saf 2015; 24: 401-2.

11. Andersen JT, Jimenez-Solem E, Andersen NL, PoulsenHE. Abstract 25, pregnancy session 1. In: ondansetronuse in early pregnancy and the risk of congenital malformations.A register based nationwide control study.Montreal (Canada): Interna- tional Society of Pharmacoepidemiology,2013.

12. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, KorenG. The safety of ondansetron for nausea and vomiting ofpregnancy: a prospective comparative study. BJOG 2004;111 (9): 940-3. doi:10.1111/j.1471-0528.2004.00236.x

13. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA; National Birth Defects PreventionStudy. Medications used to treat nausea and vomitingof pregnancy and the risk of selected birth defects.Birth Defects Res A Clin Mol Teratol 2012; 94 (1): 22-30.doi:10.1002/bdra.22865

14. Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C.Off-label use of ondansetron in pregnancy in WesternAustralia. Biomed Res Int 2013; 2013: 909860. doi:10.1155/2013/909860

15. Asker C, Norstedt Wikner B, Källén B. Use of antiemeticdrugs during pregnancy in Sweden. Eur J Clin Pharmacol2005; 61 (12): 899-906. doi: 10.1007/s00228-005-0055-1

16. Fejzo MS, MacGibbon KW, Mullin PM. Ondansetron inpregnancy and risk of adverse fetal outcomes in the UnitedStates. Reprod Toxicol 2016; 62: 87-91. doi: 10.1016/j.reprotox.2016.04.027

17. Parker SE, Van Bennekom C, Anderka M, Mitchell AA.National birth defects prevention study. Ondansetron fortreatment of nausea and vomiting of pregnancy and therisk of specific birth defects. Obstet Gynecol 2018; 132 (2):385-94. doi: 10.1097/AOG.0000000000002679

18. Bérard A, Sheehy O, Gorgui J, Zhao JP, Soares de MouraC, Bernatsky S. New evidence for concern over the riskof birth defects from medications for nausea and vomitingof pregnancy. J Clin Epidemiol 2019; 116: 39-48. doi:10.1016/j.jclinepi.2019.07.014

19. Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, PlattRW, Marroquin OC, Caritis SN. Ondansetron use in the firsttrimester of pregnancy and the risk of neonatal ventricularseptal defect. Int J Epidemiol 2020; 49 (2): 648-56. doi:10.1093/ije/dyz255

20. Dormuth CR, Winquist B, Fisher A, Wu F, Reynier P, Suissa S,Dahl M, Ma Z, Lu X, Zhang J, Raymond CB, Filion KB, Platt RW,Moriello C, Paterson JM; Canadian Network for ObservationalDrug Effect Studies (CNODES) Investigators. Comparison ofpregnancy outcomes of patients treated with ondansetronvs alternative antiemetic medications in a multinational,Population-Based Cohort. JAMA Netw Open 2021; 4 (4):e215329. doi: 10.1001/jamanetworkopen.2021.5329

21. Sakran R, Shechtman S, Arnon J, Diav-Citrin O. Pregnancyoutcome following in-utero exposure to ondansetron: A prospective comparative observationalstudy. Reprod Toxicol 2021; 99: 9-14. doi:10.1016/j.reprotox.2020.11.005

22. Masarwe S, Shvartsur R, Hadar E, Betesh-Abay B, Peleg N,Azab AN. Ondansetron use during pregnancy: birth defectsand obstetric outcomes. Clin Nurs Res 2023; 32 (4): 705-11.doi: 10.1177/10547738231159062

23. Lavecchia M, Chari R, Campbell S, Ross S. Ondansetronin Pregnancy and the Risk of Congenital Malformations:A Systematic Review. J Obstet Gynaecol Can 2018; 40 (7):910-18. doi: 10.1016/j.jogc.2017.10.024

24. Kaplan YC, Richardson JL, Keskin-Arslan E, Erol-Coskun H,Kennedy D. Use of ondansetron during pregnancy andthe risk of major congenital malformations: A systematicreview and meta-analysis. Reprod Toxicol 2019; 86: 1-13.doi: 10.1016/j.reprotox.2019.03.001

25. Picot C, Berard A, Grenet G, Ripoche E, Cucherat M, CottinJ. Risk of malformation after ondansetron in pregnancy: Anupdated systematic review and meta-analysis. Birth DefectsRes 2020; 112 (13): 996-1013. doi:10.1002/bdr2.1705

26. Cao X, Sun M, Yang Q, Wang Q, Hou L, Wang J, Wu Y, Ge L.Risk of abnormal pregnancy outcomes after using Ondansetronduring pregnancy: A systematic review and metaanalysis.Front Pharmacol 2022; 13: 951072. doi:10.3389/fphar.2022.951072

27. Committee on Practice Bulletins-Obstetrics. ACOG PracticeBulletin No. 189: Nausea and vomiting of pregnancy. ObstetGynecol 2018; 131 (1): e15-e30.